BIIB022 is a human IgG4 monoclonal antibody (mAb) targeting IGF1R/CD221. It inhibits the phosphorylation of IGF-1 and IGF-2-induced IGF-1R and its downstream substrates. BIIB022 is applicable for research in lung cancer, pancreatic cancer, and colon cancer. The recommended isotype control is Human IgG4 kappa, Isotype Control.
Target:
IGF-1R
* VAT and and shipping costs not included. Errors and price changes excepted
